Geron Corporation (NASDAQ:GERN) is one of the Most Oversold Penny Stocks to Buy Now. On August 12, Faisal Khurshid, an analyst from Leerink Partners, reiterated a Buy rating on Geron Corporation (NASDAQ:GERN) with a price target of $3.
The analyst noted that the company is taking bold steps to overcome the challenges in launching its new drug called Rytelo. Khurshid also noted the appointment of new CEO, Harout Semerjian, who brings relevant experience in hematology. The analyst sees this as a positive move toward the successful launch of Rytelo.
A close-up of a laboratory technician in a laboratory, measuring a newly developed biopharmaceutical drug.
Moreover, the management remains optimistic regarding steady growth, and the recent second-quarter results have also shown a significant increase in demand.
Geron Corporation is a biopharmaceutical company focused on developing treatments for blood disorders.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
